Pulmonx CORP

Pulmonx Corporation announced its second quarter 2026 financial results, reporting a 5% decrease in worldwide revenue to $22.8 million, but a significant reduction in net loss and adjusted EBITDA loss due to cost realignment.

Pulmonx Corporation's 2026 Annual Meeting saw strong stockholder participation and approval of director nominees, auditor ratification, and executive compensation.

Pulmonx Corporation announced its fourth quarter and full year 2025 financial results, showing full-year revenue growth and reduced losses despite a Q4 revenue decline.

Pulmonx Corporation announced its third quarter 2025 financial results, reporting a 5% increase in worldwide revenue and reaffirming its commitment to profitable growth.

Pulmonx Corporation announced a significant leadership transition, reappointing Glendon E. French as President and CEO and Derrick Sung as COO and CFO, alongside preliminary Q3 2025 revenue of $21.5 million.

Pulmonx Corporation announced its second quarter 2025 financial results, reporting strong international revenue growth but revising its full-year revenue guidance lower due to slower U.S. market conversion.

Pulmonx Corporation reported a decrease in revenue for the first quarter of 2026 compared to the prior year, primarily due to a lack of sales in China.

Pulmonx Corporation reports increased revenue in Q3 2025, driven by Zephyr Valve procedure volumes, but continues to incur significant net losses and negative cash flows from operations.

Pulmonx Corporation announced increased revenue for the second quarter and first half of 2025, driven by Zephyr Valve adoption, but reported continued net losses and a reliance on future funding to support ongoing operations and product development.

Pulmonx Corporation announces a 19.5% increase in revenue for the first quarter of 2025, driven by growth in both U.S. and international markets, while still reporting a net loss.

Pulmonx Corporation's third quarter 2024 results show a revenue increase of 15.4% year-over-year, but the company continues to operate at a net loss.

Pulmonx Corporation's second quarter 2024 results show a 20.9% increase in revenue compared to the same period last year, driven by growth in Zephyr Valve procedure volumes.

Pulmonx Corporation's FY2024 shows increased revenue and a reduced net loss compared to the previous year, driven by growth in Zephyr Valve procedure volumes.

Pulmonx Corporation's 2023 annual report reveals a 28% increase in revenue, reaching $68.7 million, alongside a net loss of $60.8 million.

Director Thomas William Burns was granted 40,000 restricted stock units in Pulmonx Corporation.

Director Richard Ferrari was granted 40,000 restricted stock units in Pulmonx Corporation.

Director Daniel P. Florin was granted 40,000 restricted stock units in Pulmonx Corporation.

Director Georgia Melenikiotou was granted 40,000 restricted stock units in Pulmonx Corporation.

Director Tiffany Sullivan was granted 40,000 restricted stock units in Pulmonx Corporation.

Pulmonx Corporation director Dana G. Mead Jr. was granted 40,000 restricted stock units as part of an equity compensation award.

Pulmonx Corporation has issued its proxy statement detailing the agenda for its 2026 Annual Meeting of Stockholders, including director elections and ratification of its independent auditor.

Pulmonx Corporation has filed a definitive proxy statement with the SEC, signaling upcoming shareholder actions.

Pulmonx Corporation's proxy statement details the agenda for the 2025 Annual Meeting of Stockholders, including director elections, auditor ratification, and executive compensation approval.

Pulmonx Corporation has filed a definitive proxy statement with the SEC, signaling upcoming shareholder actions.

Pulmonx Corporation has scheduled its 2024 Annual Meeting of Stockholders for May 16, 2024, to elect directors, ratify the selection of an independent accounting firm, and conduct an advisory vote on executive compensation.

The Vanguard Group reported a 0% beneficial ownership in Pulmonx Corp following an internal realignment, indicating a full divestment of its previously held stake.

PRIMECAP Management Co. reports a 12.16% beneficial ownership stake in Pulmonx Corporation, holding 4,956,691 shares as an investment adviser.

FMR LLC and Abigail P. Johnson have filed an amendment to their Schedule 13G, disclosing a 0.2% beneficial ownership in Pulmonx Corporation's common stock as of October 31, 2025.

FMR LLC and Abigail P. Johnson have reported a 5.4% beneficial ownership stake in Pulmonx Corp's common stock as of August 29, 2025.

FMR LLC and Abigail P. Johnson have disclosed a 10.6% beneficial ownership stake in Pulmonx Corp common stock as of June 30, 2025.

PRIMECAP Management Co/CA/ has filed an amended Schedule 13G, revealing a beneficial ownership of 13.61% in Pulmonx Corporation, totaling 5,414,761 shares as of March 31, 2025.